장마감
로그인 회원가입
PHAR
PHAR
Pharming Group NV ADR
7월 27일 4:00 PM ET (한국 7/28 05:00)
$12.78
+0.17 ▲ +1.31%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$13.01
+0.00 +0.00%

파밍 그룹(PHAR) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$905M
스몰캡
P/E
74.1
고평가 구간
배당수익률
없음
52주 위치
27%
저점 +34% · 고점 -40%
애널리스트
적극 매수
B-
Fundamental health
vs. Biotechnology 소형주
수익성 ⓘ
Top 21%
성장 ⓘ
Top 55%
밸류에이션 ⓘ
Top 43%
재무 안정 ⓘ
Top 48%
Index ⓘ -P/E ⓘ 74.13EPS (ttm) ⓘ 0.17Insider Own ⓘ -Shs Outstand ⓘ 70.1MPerf Week ⓘ -2.52%
Market Cap ⓘ 0.90BForward P/E ⓘ 35.54EPS next Y ⓘ 41.75%Insider Trans ⓘ -Shs Float ⓘ -Perf Month ⓘ -3.69%
Enterprise Value ⓘ 0.85BPEG ⓘ 0.33EPS next Q ⓘ 0.06Inst Own ⓘ 1.34%Short Float ⓘ -Perf Quarter ⓘ -23.38%
Income ⓘ 0.01BP/S ⓘ 2.44EPS this Y ⓘ 534.25%Inst Trans ⓘ 77.09%Short Ratio ⓘ 1.01Perf Half Y ⓘ -35.13%
Sales ⓘ 0.37BP/B ⓘ 3.33EPS next 5Y ⓘ 108.01%ROA ⓘ 2.73%Short Interest ⓘ 0.01MPerf YTD ⓘ -27.67%
Book/sh ⓘ 3.83P/C ⓘ 5.29EPS past 3/5Y ⓘ -41.84% -41.23%ROE ⓘ 5.05%52W High ⓘ -40.11% ($21.34)Perf Year ⓘ 24.56%
Cash/sh ⓘ 2.41P/FCF ⓘ 17.83Sales past 3/5Y ⓘ 22.4% 12.25%ROIC ⓘ 3.23%52W Low ⓘ 34.03% ($9.54)Perf 3Y ⓘ 6.5%
Dividend Est. ⓘ -EV/EBITDA ⓘ 19.59EPS Y/Y TTM ⓘ 191%Gross Margin ⓘ 87.27%Volatility(W/M) ⓘ 2.81% 3.53%Perf 5Y ⓘ 14.31%
Dividend TTM ⓘ -EV/Sales ⓘ 2.29Sales Y/Y TTM ⓘ 15.66%Oper. Margin ⓘ 8.53%ATR (14) ⓘ 0.5Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.06EPS Q/Q ⓘ 65.56%Profit Margin ⓘ 3.29%RSI (14) ⓘ 41Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 2.63Sales Q/Q ⓘ -8.14%SMA20 ⓘ -5.61% ($13.54)Beta ⓘ -0.03Target Price ⓘ $31.65
Payout ⓘ -Debt/Eq ⓘ 0.43Earnings ⓘ 2026/7/30SMA50 ⓘ -2.57% ($13.12)Rel Volume ⓘ 0.58Prev Close ⓘ $12.61
Employees ⓘ -LT Debt/Eq ⓘ 0.4EPS/Sales Surpr. ⓘ -7100% -21.3%SMA200 ⓘ -17.7% ($15.53)Avg Volume(3M) ⓘ 0.01MPrice ⓘ $12.78
IPO ⓘ 2020/12/23Option/Short ⓘ No/YesTrades ⓘ 48Volume ⓘ 5,738Change ⓘ 1.31%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Pharming Group NV ADR (PHAR) Investment Analysis

What kind of company is Pharming Group NV ADR?

파밍 그룹(PHAR) 초고성장주
Healthcare · Biotechnology
Healthcare Stocks

💊 Pharming Group (PHAR) is a Netherlands-based biopharmaceutical company focused on treatments for rare diseases. It commercializes RUCONEST, a therapy for acute attacks of hereditary angioedema, and Joenja (leniolisib), a treatment for activated phosphoinositide 3-kinase delta syndrome (an ultra-rare immune disorder), primarily in the United States. The company is growing on the back of high gross margins and deep expertise in rare diseases. Listed in the U.S. as an ADR, the stock is accessible to global investors.

Learn more about Pharming Group NV ADR →
Market Cap
$0.9B
Approx. KRW 1.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2719
IPO2020/12/23
Current Price$12.78 ≈ 17,509원
NASD · Netherlands

Key Events

⏰ Upcoming events
🔔 Earnings release D-2
7월 30일 (목) · 장 시작 전
예상 매출 - · EPS $0.06
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS -7100.0% 매출 -21.3%
🔔 Earnings release 2026년 3월 12일 (목) · 장 시작 전 EPS +366.7% 매출 -4.7%

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
8.5%
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology 소형주 Median -210.9% · Top 11%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
3.3%
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology 소형주 Median -187.6% · Top 20%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
87.3%
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology 소형주 Median 84.9% · Top 43%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
5.0%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -37.5% · Top 17%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
2.7%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -21.8% · Top 17%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
3.2%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -25.0% · Top 17%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.43
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
2.63
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.06
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$31.65
현재가 대비 +147.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
35.54배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.33
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+41.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+108.0%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
-3320.0%
평균 서프라이즈
2026.05.07
하회
실적 $-0.07 · 예상 $0.00 -7100.0%
2026.03.12
상회
실적 $0.07 · 예상 $0.01 +460.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Turnaround Expected
Past performance was weak, but the outlook is positive
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+534.3%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 51.6% · Top tier
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+41.8%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 33.7% · Top 44%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+108.0%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 40.0% · Top tier
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-41.8%
부진
My positionBottom 25%
Low range Average High range
초고성장주 소형주 Median 6.9% · Bottom 16%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-41.2%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 7.0% · Bottom tier
Past 5-Year Revenue
How much revenue grew over the past 5 years
+12.3%
평균
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 32.4% · Bottom 26%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-8.1%
부진
My positionBottom 25%
Low range Average High range
초고성장주 소형주 Median 14.5% · Bottom 18%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -54%p below the market
PHAR +14.3% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-54.0%p
Significantly behind the market
vs Health Care (XLV)
-10.2%p
behind the sector average
1-year basis
vs S&P 500
+8.5%p
slightly ahead of the market
vs Health Care (XLV)
+4.8%p
roughly in line with the sector average
Rank among peers
5-year return Top 21% Based on 123 peers
1-year return Lower-Mid (lower 39%) Based on 154 peers
Current position within 52-week range
Low (-34.0%p) High (-40.1%p)
Current price is 34.0% above the 52-week low and 40.1% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-32.6%
Annualized volatility
60.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $12.78 below the midline ($13.51). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.143 < Signal -0.030 in negative zone + Hist negative (-0.113). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 41.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 9.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Assets·Vs. Sales, Pricey on Vs. Earnings, In line with peers on Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Pricey
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Mid-range
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
74.13x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Biotechnology 소형주 median 7.65x · Bottom 1% — expensive within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
35.54x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 소형주 median 18.33x · Bottom 20% — expensive within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.33x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 소형주 median 3.34x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
2.44x
✓ Very cheap
My positionTop 25%
Low range Average High range
Biotechnology 소형주 median 14.61x · Top 11% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
19.59x
✓ Fair
My positionMid-range
Low range Average High range
Biotechnology 소형주 median 19.26x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
17.83x
✓ Fair
My positionMid-range
Low range Average High range
Biotechnology 소형주 median 14.14x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$31.65 vs. current price +147.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow is positive
Institutional net buying +77.1%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-
No trading data for Insiders
🏦 Institutions (funds & investors)
+77.1%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 1.3%
Retail-led
Healthcare 소형주 Median 65.6%
👤 Retail investors (estimated) 98.7%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
-
Short interest days to cover
1.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 70.1M주
Float (tradable shares) -
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 0 days.

ETFs holding PHAR

ETFs with the highest weightings · 10 total shown
EWN
EWN
iShares MSCI Netherlands ETF
0.37%
$567M
FDTS
FDTS
First Trust Developed Markets ex-US Small Cap AlphaDEX Fund
0.17%
$13M
GWX
GWX
State Street SPDR S&P International Small Cap ETF
0.09%
$857M
IEUS
IEUS
iShares MSCI Europe Small-Cap ETF
0.08%
$176M
BAMD
BAMD
Brookstone Dividend Stock ETF
0.05%
$99M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PHAR PHAR This Stock
$904.6M74.1 ▼3.3 ▼5.05% ▲- +1.3%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Derivative ETFs for PHAR

Leveraged, inverse, and covered call ETFs based on the underlying asset

2 derivative ETFs based on PHAR (Leverage 2)
These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.
ℹ️ What is a Derivative ETF?
These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.
⚠️ Caution: Long-Term Holding
Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.
📈 Leverage 2 ETFs that move 2-3x with PHAR (high volatility)
BIB
BIB
ProShares Ultra Nasdaq Biotechnology 2X Shares
+0.50%
$82M
PILL
PILL
Direxion Daily Pharmaceutical & Medical Bull 3X ETF
+3.15%
$21M
🧺
Deeper Analysis at the ETF Center ETF overlap, sector exposure, and X-Ray analysis tools
→

Related News & Content

📖 Company overview
파밍 그룹(PHAR) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
파밍 그룹(PHAR)은 희귀질환 치료제 RUCONEST와 Joenja를 중심으로 성장하는 네덜란드 기반 바이오제약 기업으로, 높은 총마진과 미국 매출 확대, 파이프라인 진전이 주가와 실적 전망을 좌우하는 핵심 요인으로 꼽힙니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 파밍 그룹(PHAR)?

파밍 그룹(PHAR) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PHAR?

The market cap of PHAR is approximately $905M, ranking 2,719 within its sector.

What is the P/E ratio of PHAR?

PHAR has a P/E ratio of approximately 74.1x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for PHAR?

PHAR has recorded a 52-week high of $21.34 and a low of $9.54.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.